Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
GitLab's Flex Headwind Smaller Than Expected, H2 Pipeline Remains Healthy, UBS Securities Says

GitLab's Flex Headwind Smaller Than Expected, H2 Pipeline Remains Healthy, UBS Securities Says

MT newswireMT newswire2026/09/14 16:40
12:40 PM EDT, 09/14/2026 (MT Newswires) -- GitLab's (GTLB) Flex offering may create a smaller revenue headwind than expected, while its H2 pipeline remains healthy despite some early renewals in Q2, UBS Securities said in a note Sunday. The investment firm estimated that Flex could reduce fiscal 2028 revenue growth by about 1 to 2 percentage points as adoption is likely to be "slower and more phased." Public-sector contracting limitations, large deals already in progress, and limited availability in some international markets could delay customer adoption, according to the note. The near-term opportunity in artifact management appears more "modest" than previously anticipated, with GitLab now expecting a mix of new deployments and replacements rather than widespread displacement of JFrog (FROG), the firm said. Competition from artificial intelligence-native source code management tools, including Cursor Origin, remains a concern, though early growth in non-developer seats could expand GitLab's addressable market over time, the firm said. UBS Securities has a neutral rating on GitLab, with a price target of $50. GitLab shares were up more than 4% in Monday trading. Price: 48.96, Change: +1.97, Percent Change: +4.19
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage